CIPLA.NS Cipla
₹1,307 -1.54%
Asia · Healthcare
RSI (14) · 30 / 70 bands
MACD (12, 26, 9)
Solid = close · dashed = 50-day MA · bars = volume. Toggle Bollinger / RSI / MACD. Hover to inspect. EOD data.
1D
-1.54%
YTD
-12.60%
P/E
—
P/B
—
ROE
—
Div yield
—
Beta
0.12
Market cap
—
RSI (14)
28
Next earnings
—
Previous session
close of Oct 8, 2026 · EOD, no live order bookOpen
₹1,323
Close
₹1,307
VWAP (n/a)
—
Day high
₹1,334
Day low
₹1,292
Volume
552K
VWAP = daily turnover ÷ volume — the volume-weighted average, the closest EOD read on where trading actually clustered. A true order book is live-only and needs a broker feed. Turnover/VWAP available for MOEX listings.
Latest headlines
Ritedose Appoints Carolyn Berg as New Vice President of Strategic Growth
Yahoo Finance · Sep 10
Cipla Announces Exclusive Partnership with Qilu Pharmaceutical for the Licensing and Supply of Biosimilar to Keytruda® (Pembrolizumab) in the US
Yahoo Finance · Sep 3
Cipla Receives U.S. FDA Approval for Generic Advair Diskus®
Yahoo Finance · Jul 28
Cipla Expands U.S. Respiratory Portfolio with Approval of Nintedanib Capsules (100mg & 150mg) for Idiopathic Pulmonary Fibrosis
Yahoo Finance · Apr 3
Cipla Receives U.S. FDA Approval for First AB-Rated Generic of Ventolin® HFA
Yahoo Finance · Apr 23
Merck's $8.4 Billion Keytruda Fortress Gets a 2028 Warning
Yahoo Finance · Sep 3
Headlines via Yahoo Finance · links open the source · not an endorsement.
Research & reports
External resources — availability and opinions are theirs, not ours.
This is reference data for your own analysis — not a recommendation to buy or sell CIPLA.NS. Try it in the Lab to size a position and see the risk.